Amylin agonist compounds for estrogen-deficient mammals
AssigneeAmylin Pharamaceuticals, Inc.
InventorsJonathan David Roth, James L. Trevaskis, David G. Parkes
Life of this patent
Estimating the term…
Abstract
Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
Claims21
1-99. (canceled)
A method for treating estrogen deficiency in a mammal in need thereof comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound.
A method for treating obesity or overweight in an estrogen-deficient mammal comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound to treat the obesity or overweight in the mammal.
A method for reducing weight in an estrogen-deficient mammal comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound.
A method of increasing Bdnf levels in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of an amylin agonist compound to increase Bdnf levels in the mammal.
Dependencies are inferred from the claim text.